Literature DB >> 15974158

The effects of race and criminal justice involvement on access to atypical antipsychotic medications among persons with schizophrenia.

Richard A Van Dorn1, Jeffrey W Swanson, Marvin S Swartz, Eric B Elbogen.   

Abstract

This study examined the impact of race and arrest history on the likelihood of being prescribed, and maintaining an atypical antipsychotic prescription for 90 or more days among patients with schizophrenia in the community. Participants were 224 adults with schizophrenia-spectrum disorders receiving services in public-sector mental health systems in North Carolina. The data used for this report were from a subsample of a larger group of participants being followed in an observational study and consisted of individuals who were prescribed either an atypical or conventional antipsychotic medication for 90 or more days. The purpose of the analyses presented here was to investigate differences in the likelihood of being prescribed an atypical antipsychotic by demographic and other characteristics. Logistic regression analysis indicated that African American patients were significantly less likely to receive atypical antipsychotics than their white counterparts, even when controlling for key clinical and demographic variables. However, white patients with a history of arrest were no more likely than black patients to receive atypical antipsychotics; that is, minority racial status and criminal involvement each functioned to limit patients' access to the novel medications. Implications for equal access to mental health services, in this case, effective psychopharmacologic treatment, are discussed.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15974158     DOI: 10.1007/s11020-005-3783-z

Source DB:  PubMed          Journal:  Ment Health Serv Res        ISSN: 1522-3434


  3 in total

1.  Longitudinal treatment outcome of African American and Caucasian patients with first episode psychosis.

Authors:  Huijun Li; Shaun M Eack; Debra M Montrose; Jean M Miewald; Matcheri Keshavan
Journal:  Asian J Psychiatr       Date:  2011-10-12

2.  The 3-year clinical and functional course of schizophrenia among individuals with and without diabetes at study entry.

Authors:  Haya Ascher-Svanum; Baojin Zhu; Frank R Ernst; Douglas E Faries; Jennie G Jacobson; Caroline C Doebbeling
Journal:  Prim Care Companion J Clin Psychiatry       Date:  2007

3.  Impact of race on efficacy and safety during treatment with olanzapine in schizophrenia, schizophreniform or schizoaffective disorder.

Authors:  Virginia L Stauffer; Jennifer L Sniadecki; Kevin W Piezer; Jennifer Gatz; Sara Kollack-Walker; Vicki Poole Hoffmann; Robert Conley; Todd Durell
Journal:  BMC Psychiatry       Date:  2010-11-03       Impact factor: 3.630

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.